UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Constitutional BRCA1 Epimutations: A Key for Understanding Basal‐Like Breast and High‐Grade Serous Ovarian Cancer

Human mutation, 2024-01, Vol.2024 (1)

2024

Volltextzugriff (PDF)

C/EBPB-dependent adaptation to palmitic acid promotes tumor formation in hormone receptor negative breast cancer

Nature communications, 2022-01, Vol.13 (1), p.69-69, Article 69

2022

Volltextzugriff (PDF)

Interpreting plasma estrogen levels in breast cancer: caution needed

Journal of clinical oncology, 2014-05, Vol.32 (14), p.1396-1400

2014

Volltextzugriff (PDF)

Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation

Journal of investigative dermatology, 2015-07, Vol.135 (7), p.1820-1828

2015

Volltextzugriff (PDF)

Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer

Journal of clinical oncology, 2016-05, Vol.34 (14), p.1580-1583

2016

Volltextzugriff (PDF)

Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study

Journal of clinical oncology, 2012-03, Vol.30 (7), p.709-717

2012

Volltextzugriff (PDF)

Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon

International journal of cancer, 2015-07, Vol.137 (1), p.96-103

2015

Volltextzugriff (PDF)

Demystifying BRAF Mutation Status in Colorectal Liver Metastases : A Multi-institutional, Collaborative Approach to 6 Open Clinical Questions

Annals of surgery, 2023-09, Vol.278 (3), p.e540-e548

2023

Volltextzugriff (PDF)

Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy

BMC cancer, 2012-01, Vol.12 (1), p.39-39, Article 39

2012

Volltextzugriff (PDF)

Assessing Novel Therapies Based on Late-Stage Efficacy: A Dangerous Concept?

Trends in Cancer, 2021-03, Vol.7 (3), p.181-185

Lønning, Per E

2021

Volltextzugriff (PDF)

Adjuvant Aromatase Inhibitors for Early Breast Cancer After Chemotherapy-Induced Amenorrhoea: Caution and Suggested Guidelines

Journal of clinical oncology, 2006-06, Vol.24 (16), p.2444-2447

2006

Volltextzugriff (PDF)

Repeated Observation of Breast Tumor Subtypes in Independent Gene Expression Data Sets

Proceedings of the National Academy of Sciences - PNAS, 2003-07, Vol.100 (14), p.8418-8423

2003

Volltextzugriff (PDF)

White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk

Annals of internal medicine, 2018-03, Vol.168 (5), p.326

2018

Volltextzugriff (PDF)

Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC

Cancer & metabolism, 2019-06, Vol.7 (1), p.6-6, Article 6

2019

Volltextzugriff (PDF)

Predicting long-term survival and treatment response in breast cancer patients receiving neoadjuvant chemotherapy by MR metabolic profiling

NMR in biomedicine, 2012-02, Vol.25 (2), p.369-378

2012

Volltextzugriff (PDF)

Effects of Exemestane Administered for 2 Years Versus Placebo on Bone Mineral Density, Bone Biomarkers, and Plasma Lipids in Patients With Surgically Resected Early Breast Cancer

Journal of clinical oncology, 2005-08, Vol.23 (22), p.5126-5137

2005

Volltextzugriff (PDF)

Molecular basis for therapy resistance

Molecular oncology, 2010-06, Vol.4 (3), p.284-300

Lønning, Per E.

2010

Volltextzugriff (PDF)

MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk

Oncotarget, 2011-03, Vol.2 (3), p.251-258

2011

Volltextzugriff (PDF)

TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy

Acta oncologica, 2014-10, Vol.53 (10), p.1347-1355

2014

Volltextzugriff (PDF)

Poor-prognosis estrogen receptor- positive disease: present and future clinical solutions

Therapeutic Advances in Medical Oncology, 2012-05, Vol.4 (3), p.127-137

Lønning, Per E.

2012

Volltextzugriff (PDF)

Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk

Transcription, 2011-09, Vol.2 (5), p.207-210

2011

Volltextzugriff (PDF)

NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients

Breast cancer research : BCR, 2018-10, Vol.20 (1), p.120-120, Article 120

2018

Volltextzugriff (PDF)

Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines

Oncotarget, 2017-06, Vol.8 (25), p.41227-41241

2017

Volltextzugriff (PDF)

Comment on "Towards a personalized approach to aromatase inhibitor therapy: a digital microfluidic platform for rapid analysis of estradiol in core-needle-biopsies" by S. Abdulwahab, A. H. C. Ng, M. D. Chamberlain, H. Ahmado, L.-A. Behan, H. Gomaa, R. F. Casper and A. R. Wheeler, Lab Chip, 2017, 17, 1594

Lab on a chip, 2017-09, Vol.17 (18), p.3186-3187

Lønning, Per E

2017

Volltextzugriff (PDF)

1 – 25 von 226

Suche als RSS-Feed

Aktive Filter

KollektionOxford journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(218)
Mit Volltextzugriff
(204)

Publikationsform

Artikel
(225)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Constitutional BRCA1 Epimutations: A Key for Understanding Basal‐Like Breast and High‐Grade Serous Ovarian Cancer

C/EBPB-dependent adaptation to palmitic acid promotes tumor formation in hormone receptor negative breast cancer

Interpreting plasma estrogen levels in breast cancer: caution needed

Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation

Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer

Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study

Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon

Demystifying BRAF Mutation Status in Colorectal Liver Metastases : A Multi-institutional, Collaborative Approach to 6 Open Clinical Questions

Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy

Assessing Novel Therapies Based on Late-Stage Efficacy: A Dangerous Concept?

Adjuvant Aromatase Inhibitors for Early Breast Cancer After Chemotherapy-Induced Amenorrhoea: Caution and Suggested Guidelines

Repeated Observation of Breast Tumor Subtypes in Independent Gene Expression Data Sets

White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk

Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC

Predicting long-term survival and treatment response in breast cancer patients receiving neoadjuvant chemotherapy by MR metabolic profiling

Effects of Exemestane Administered for 2 Years Versus Placebo on Bone Mineral Density, Bone Biomarkers, and Plasma Lipids in Patients With Surgically Resected Early Breast Cancer

Molecular basis for therapy resistance

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk

TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy

Poor-prognosis estrogen receptor- positive disease: present and future clinical solutions

Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk

NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients

Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines

Aktive Filter

Suchergebnisse filtern